For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need more than headline growth figures. Executive Summary […]

A patent does not generate revenue. A masterfully executed commercial strategy does. This guide breaks down exactly how pharmaceutical companies,

1. The Structural Economics of Generic Affordability 1.1 The Arithmetic Behind the 80-85% Discount Generic drugs fill roughly 90% of

The economic lifeblood of a pharmaceutical company is the period of market exclusivity granted by its patent portfolio. For most

The global biologics market crossed $400 billion in annual revenue in 2023 and is tracking toward $600 billion by 2026

Section 1: What ‘Pharmerging’ Actually Means in 2025 Defining the Tier Structure IQVIA’s ‘pharmerging’ classification groups approximately 21 countries by

Generics account for over 90% of all U.S. prescriptions filled while consuming roughly 18% of total prescription drug spending. That

A data-driven deep dive into Hatch-Waxman mechanics, ANDA strategy, Paragraph IV litigation economics, patent IP valuation, complex generics science, and

1. Why Drug Patent Portfolio Management Determines Who Wins — and Who Exits {#1} Pharmaceutical R&D is one of the